Mechanistically, the study identified modulation of the PI3K/AKT signaling pathway, a key driver of GBM, supporting the notion that these synthetic endocannabinoid analog may exert their anti‐cancer effects through receptor‐mediated and downstream metabolic mechanisms. This evidence concerns the gene AKT1 and cancer.